Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Eli Lilly and : Lilly, UnitedHealth Partner in Study of Bamlanivimab in Covid-19

12/04/2020 | 08:37am EST

By Michael Dabaie

Eli Lilly & Co. and UnitedHealth Group Inc. said they are in a partnership to conduct a study under real-world conditions of bamlanivimab, or LY-CoV555, in high-risk, Covid-19 infected individuals.

The study will treat a large, diverse population of high-risk individuals for Covid-19 with bamlanivimab under real-world conditions with a goal of reducing the severity of illness and hospitalizations, the companies said Friday.

Bamlanivimab recently received emergency use authorization from the U.S. Food and Drug Administration for treatment of mild to moderate Covid-19 patients at high risk for progressing to severe Covid-19 and hospitalization, Lilly said.

The trial will evaluate bamlanivimab versus a control in people that meet the emergency use authorization criteria.

It will draw on both UnitedHealth's UnitedHealthcare health benefits business as well as its Optum health services business to detect and treat high-risk symptomatic patients who test positive for Covid-19, including daily symptom tracking, in-home SARS-CoV-2 testing and in-home infusion services.

"While bamlanivimab is authorized for emergency use based on the efficacy and safety data accumulated to date, larger pragmatic studies in diverse populations can help us further understand the efficacy and safety of SARS-CoV-2 neutralizing antibodies in real world settings," said Daniel Skovronsky, Lilly's chief scientific officer and president of Lilly Research Laboratories.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

12-04-20 0836ET

Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 2.19% 190.77 Delayed Quote.12.99%
UNITEDHEALTH GROUP 0.22% 351.3 Delayed Quote.-0.04%
All news about ELI LILLY AND COMPANY
05:03pELI LILLY AND : Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 ..
PR
09:16aELI LILLY AND COMPANY : - Gabrielle Sulzberger Elected to Lilly Board of Directo..
AQ
07:09aELI LILLY AND : Lilly Invests $30 Million in Venture Fund for Underrepresented F..
DJ
06:57aELI LILLY AND : Invests $30 Million in Venture Capital Fund Targeting Early-Stag..
MT
01/14INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Eli Lilly
MT
01/14ELI LILLY & CO : Change in Directors or Principal Officers, Financial Statements..
AQ
01/14ELI LILLY AND : Gabrielle Sulzberger Elected to Lilly Board of Directors
PR
01/13ELI LILLY AND : (LLY) sees Significant Insider Selling
MT
01/13Equities End Mixed as House Votes on Impeaching President Trump for Second Ti..
MT
01/12INSIDER TRENDS : Insider Sales Continue 90-Day Trend at Eli Lilly
MT
More news
Financials (USD)
Sales 2020 24 408 M - -
Net income 2020 5 802 M - -
Net Debt 2020 11 301 M - -
P/E ratio 2020 30,0x
Yield 2020 1,56%
Capitalization 173 B 173 B -
EV / Sales 2020 7,55x
EV / Sales 2021 6,63x
Nbr of Employees 33 625
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 181,58 $
Last Close Price 190,77 $
Spread / Highest target 19,0%
Spread / Average Target -4,82%
Spread / Lowest Target -37,1%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY12.99%169 250
JOHNSON & JOHNSON2.08%422 918
ROCHE HOLDING AG0.99%301 476
NOVARTIS AG-0.16%214 006
MERCK & CO., INC.0.45%207 893
PFIZER INC.-0.16%204 271